Emmjay....The company has published results from a MEDAcorp...

Emmjay....The company has published results from a MEDAcorp survey (Aug 2010) of oncologists several times re whether they would choose to change from irinotecan to HA-I given the results from PhII. eg. see Slide 13 of
http://www.alchemia.com.au/IRM/Company/ShowPage.aspx/PDFs/1737-28028727/AusBiotechPresentation

The results indicated that there would be a significant migration to HA-I.

I thought it was thorough for them to do that market research and not just assume a drug with higher efficacy would be automatically taken up by the sector.

This doesn't address the overall HyACT platform, but that sort of migration from a drug with a pre-generic $1B market is indicative of strong market demand.

But I'm not sure whether you're asking about oncologist demand or big pharma interest. The main thing is that the market (oncologists) want it.